
3 No-Brainer Dividend Stocks to Buy in September
The attraction of these dividend stocks isn't limited to their dividends.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
The attraction of these dividend stocks isn't limited to their dividends.
Dividends are powerful portfolio boosters, and AbbVie is a dividend dynamo.
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
The Vanguard High Dividend Yield Index Fund ETF is a low-cost fund that holds nearly 600 stocks and yields 2.5%.
These stocks have what it takes to succeed over the long run.
TORONTO and HAIFA, Israel, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc. ( TSXV: NRX ) ( OTCQB: NRXBF ) ( FSE: J90 ) ( "NurExone" or the "Company" ) , a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following ...
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
AbbVie's growth prospects are now more secure thanks to its latest news.
AbbVie's settlement prevents generic competition for upadacitinib tablets until April 2037 in the U.S. Pediatric exclusivity could further extend Rinvoq's market protection under the agreement. Get the strategy to turn September's volatility into 10x trades → AbbVie Inc.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) will host an Investor Day in New York City today. Senior executives will provide an update on the company's plans to drive shareholder value creation through its unique business model and capabilities in the large ...
On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive ...
Most of them have at least one very redeeming quality at this point, but one has proverbially painted itself into a corner.
You can have the best of both worlds with this ETF.
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Fidelity's FBIOX, FSPHX and FSMEX stand out as top-ranked healthcare mutual funds offering stability and steady returns.
If investors select their dividend-paying stocks in a structured manner, they can create a portfolio that provides monthly paydays.
AbbVie (ABBV) closed at $210 in the latest trading session, marking a -1.2% move from the prior day.
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
This ETF is a low-cost way to generate a high yield from a variety of stocks.
This company's past ability to extend patent-protected market exclusivity for its drugs bodes well for new investors.
Investors can feel good about upping their bets on these great dividend stocks.
SAN DIEGO, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- ADARx Pharmaceuticals, Inc. ( ADARx ) , a late-stage clinical biotechnology company developing next-generation RNA therapeutics, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025.
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
There is more to like than the dividend with these companies.
AbbVie ABBV has outperformed the market over the past 5 years by 4.54% on an annualized basis producing an average annual return of 18.62%. Currently, AbbVie has a market capitalization of $375.08 billion.
NEW YORK, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following ( collectively, the "Notes" ...
MENLO PARK, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc.
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
NEW YORK and WALTHAM, Mass., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Zenas BioPharma, Inc. ( Nasdaq: ZBIO ) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease ...
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
Style Box ETF report for ...
The pharmaceutical giant currently offers a 7% yield, but dividend investors need to look beyond the headline number.
Selling these dividend stocks isn't on my radar at all.
You won't need a lot of money up front to begin raking in dividends from these great stocks.
PepsiCo is investing $585 million to raise its Celsius stake to 11%. AbbVie will acquire Gilgamesh Pharmaceuticals' lead investigational candidate for moderate-to-severe major depressive disorder. Bain Capital's Chindata China data center business boasts a valuation of about 30 billion yuan ( ...
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Delhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Global Market Current Size Insight In US$ Billion: 2022 - 2030 Global Market Opportunity: > US$ 90 Billion